Driven by the central role of NF-κB signaling and MYD88 in MZL, we studied the pharmacological inhibition of IRAK4 with emavusertib in two MZL cell lines and their derivatives with acquired resistance to FDA approved PI3K and BTK inhibitors. Here, IRAK4 is linked to marginal zone lymphoma.